FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283777009> ?p ?o ?g. }

• W4283777009 endingPage "1032" @default.
• W4283777009 startingPage "1021" @default.
• W4283777009 abstract "BACKGROUND: Systemic lupus erythematosus (SLE) is a complex clinical diagnosis historically aided by imperfect biomarkers. The advent of a multianalyte assay panel incorporating innovative cell-bound complement activation markers necessitates a comparison of its clinical utility to conventional autoantibodies for the diagnosis and treatment of SLE. OBJECTIVES: To compare the likelihood of SLE diagnosis, SLE treatment initiation, and the downstream impact on health care utilization among patients tested with AVISE Lupus (AVISE) vs standard-of-care laboratory testing with the traditional antinuclear antibody (ANA) testing strategy cohort (tANA). METHODS: An observational retrospective cohort study was conducted using electronic health record (EHR) data from the Illumination Health registry, which integrates EHR records from more than 300 rheumatologists across the US. Health records from January 2016 to December 2020 and administrative claims with cost data for a subset of patients linkable to the HealthCore Integrated Research Database and Medicare data were analyzed. The AVISE and tANA test results were classified as positive, negative, or indeterminate, and outcomes were stratified based on test results. Two cohorts were established: AVISE testing strategy and the tANA approach. Analyses included test impact on SLE diagnosis, treatment initiation, patterns of repeat testing, and downstream health care utilization. Multivariable logistic regression was used to estimate odds ratios (ORs) comparing the likelihood of SLE medication initiation and SLE diagnosis between the AVISE and tANA cohorts. RESULTS: The main cohort included 21,827 AVISE testing episodes and 22,778 tANA testing episodes. A total of 2,437 (11.2%) patients tested positive by AVISE compared with 5,364 (23.6%) of tANA positive patients. Among patients with no baseline prescription for SLE medication(s), patients with a positive AVISE test result were more likely to initiate SLE medications compared with tANA positive patients (43% vs 32%; OR = 1.57; 95% CI = 1.41-1.76). The treatment effect was larger in patients new to the practice within the preceding year (55% vs 33%; adjusted OR = 2.77; 95% CI = 2.31-3.32). AVISE positive patients were more than 5-fold more likely to be diagnosed with SLE, as compared with the tANA patients (31% vs 8%; OR = 5.11; 95% CI = 4.43-5.89), and similar in the new patient cohort (30% vs 6%; OR = 6.34; 95% CI = 5.12-7.86). Linked EHR-Medicare data revealed a greater decrease in posttest vs pretest mean annualized outpatient laboratory testing in AVISE negative (-$985; P < 0.0001) vs tANA negative (-$356; P < 0.0001) patients. A similar analysis in the EHR-HealthCore linked data revealed similar numerical trends as the Medicare data for outpatient laboratory testing but did not reach significance (P > 0.05). Cost comparisons in the categories of hospitalization, emergency department, outpatient imaging, and pharmacy costs did not yield significant differences. CONCLUSIONS: The significantly greater likelihood of SLE diagnosis and SLE medication initiation in AVISE positive vs tANA positive patients is consistent with improved clinical actionability, potentially shortening time to diagnosis. AVISE negative patients experienced a greater decrease in outpatient laboratory testing posttest relative to tANA negative patients, supporting the improved negative predictive value of AVISE vs tANA. DISCLOSURES: Mr O'Malley and Dr Zack are employed by Exagen Inc. Drs Curtis and Xie, Ms Su, and Ms Clinton are affiliated with the University of Alabama at Birmingham. Mr Haechung and Dr Grabner are employees of HealthCore, Inc., which received funding from Bendcare (owner of the Illumination Health Registry) for the conduct of parts of the study on which this manuscript is based. Exagen Inc. provided funding to Bendcare for the conduct of the study. Dr Grabner is also a shareholder of Anthem, Inc." @default.
• W4283777009 created "2022-07-03" @default.
• W4283777009 creator A5000754711 @default.
• W4283777009 creator A5009635354 @default.
• W4283777009 creator A5023968177 @default.
• W4283777009 creator A5039374545 @default.
• W4283777009 creator A5043053903 @default.
• W4283777009 creator A5064518028 @default.
• W4283777009 creator A5078965365 @default.
• W4283777009 creator A5090788600 @default.
• W4283777009 date "2022-09-01" @default.
• W4283777009 modified "2023-10-18" @default.
• W4283777009 title "Complement activation products vs standard ANA testing: Treatment outcomes, diagnosis, and economic impact (CAPSTONE) in systemic lupus erythematosus" @default.
• W4283777009 cites W2002008626 @default.
• W4283777009 cites W2004135257 @default.
• W4283777009 cites W2017199270 @default.
• W4283777009 cites W2093076036 @default.
• W4283777009 cites W2098364806 @default.
• W4283777009 cites W2135341222 @default.
• W4283777009 cites W2139198208 @default.
• W4283777009 cites W2144599313 @default.
• W4283777009 cites W2159657555 @default.
• W4283777009 cites W2410325454 @default.
• W4283777009 cites W2604241349 @default.
• W4283777009 cites W2746608454 @default.
• W4283777009 cites W2901509748 @default.
• W4283777009 cites W2965565685 @default.
• W4283777009 cites W2970752536 @default.
• W4283777009 cites W2974487453 @default.
• W4283777009 cites W3010743646 @default.
• W4283777009 cites W3014190183 @default.
• W4283777009 cites W3027592429 @default.
• W4283777009 cites W3119121025 @default.
• W4283777009 cites W3124692866 @default.
• W4283777009 cites W3129100984 @default.
• W4283777009 cites W3143803880 @default.
• W4283777009 cites W3181825500 @default.
• W4283777009 cites W993570101 @default.
• W4283777009 doi "https://doi.org/10.18553/jmcp.2022.22039" @default.
• W4283777009 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35775579" @default.
• W4283777009 hasPublicationYear "2022" @default.
• W4283777009 type Work @default.
• W4283777009 citedByCount "0" @default.
• W4283777009 crossrefType "journal-article" @default.
• W4283777009 hasAuthorship W4283777009A5000754711 @default.
• W4283777009 hasAuthorship W4283777009A5009635354 @default.
• W4283777009 hasAuthorship W4283777009A5023968177 @default.
• W4283777009 hasAuthorship W4283777009A5039374545 @default.
• W4283777009 hasAuthorship W4283777009A5043053903 @default.
• W4283777009 hasAuthorship W4283777009A5064518028 @default.
• W4283777009 hasAuthorship W4283777009A5078965365 @default.
• W4283777009 hasAuthorship W4283777009A5090788600 @default.
• W4283777009 hasConcept C126322002 @default.
• W4283777009 hasConcept C151956035 @default.
• W4283777009 hasConcept C167135981 @default.
• W4283777009 hasConcept C177713679 @default.
• W4283777009 hasConcept C194828623 @default.
• W4283777009 hasConcept C201903717 @default.
• W4283777009 hasConcept C2776912625 @default.
• W4283777009 hasConcept C2779134260 @default.
• W4283777009 hasConcept C71924100 @default.
• W4283777009 hasConcept C72563966 @default.
• W4283777009 hasConceptScore W4283777009C126322002 @default.
• W4283777009 hasConceptScore W4283777009C151956035 @default.
• W4283777009 hasConceptScore W4283777009C167135981 @default.
• W4283777009 hasConceptScore W4283777009C177713679 @default.
• W4283777009 hasConceptScore W4283777009C194828623 @default.
• W4283777009 hasConceptScore W4283777009C201903717 @default.
• W4283777009 hasConceptScore W4283777009C2776912625 @default.
• W4283777009 hasConceptScore W4283777009C2779134260 @default.
• W4283777009 hasConceptScore W4283777009C71924100 @default.
• W4283777009 hasConceptScore W4283777009C72563966 @default.
• W4283777009 hasIssue "9" @default.
• W4283777009 hasLocation W42837770091 @default.
• W4283777009 hasLocation W42837770092 @default.
• W4283777009 hasOpenAccess W4283777009 @default.
• W4283777009 hasPrimaryLocation W42837770091 @default.
• W4283777009 hasRelatedWork W188703148 @default.
• W4283777009 hasRelatedWork W1971557041 @default.
• W4283777009 hasRelatedWork W2021599063 @default.
• W4283777009 hasRelatedWork W2076300443 @default.
• W4283777009 hasRelatedWork W2360736373 @default.
• W4283777009 hasRelatedWork W2543548379 @default.
• W4283777009 hasRelatedWork W2969962500 @default.
• W4283777009 hasRelatedWork W3091109908 @default.
• W4283777009 hasRelatedWork W3157198265 @default.
• W4283777009 hasRelatedWork W3197850556 @default.
• W4283777009 hasVolume "28" @default.
• W4283777009 isParatext "false" @default.
• W4283777009 isRetracted "false" @default.
• W4283777009 workType "article" @default.